RXRX Stock: Price, Earnings History and SEC Filings
Recursion Pharmaceuticals, Inc. (RXRX) last traded at $4.03, down 4.95% on the latest session and down 2.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.25 against an analyst estimate of $-0.23, a miss of 8.7%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RXRX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-0.25 | $-0.23 | -8.70% |
| Mar 2026 | May 6, 2026 | $-0.22 | $-0.30 | +26.67% |
| Dec 2025 | Feb 25, 2026 | $-0.21 | $-0.28 | +25.00% |
| Sep 2025 | Nov 5, 2025 | $-0.36 | $-0.38 | +5.26% |
RXRX beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How RXRX reacts to earnings
Across its last 8 earnings releases, RXRX moved 6.0% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-15 | Before open | +11.23% |
| 2026-08-05 | Before open | -4.23% |
| 2026-05-06 | Before open | +1.78% |
| 2026-02-25 | Before open | +6.80% |
| 2025-11-05 | Before open | -0.80% |
| 2025-08-05 | Before open | -4.66% |
| 2025-05-05 | Before open | -16.58% |
| 2025-02-28 | Before open | -2.09% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
RXRX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $75M | -$645M | -$378M | -863.4% | $-1.44 |
| 2024 | $59M | -$464M | -$373M | -788.0% | $-1.69 |
| 2023 | $45M | -$328M | -$300M | -736.0% | $-1.58 |
| 2022 | $40M | -$239M | -$121M | -601.0% | $-1.36 |
| 2021 | $10M | -$186M | -$198M | -1832.2% | $-1.49 |
| 2020 | $4M | -$87M | -$51M | -2196.0% | $-3.99 |
| 2019 | $2M | -$62M | -$61M | -2668.3% | $-2.87 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for RXRX
- 424B5 · Oct 15, 2026
- 8-K · Oct 15, 2026Material agreement, Results of operations, Regulation FD disclosure
- 424B5 · Oct 15, 2026
- 8-K · Sep 21, 2026Material agreement
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 18, 2026Shareholder vote
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- DEF 14A · Apr 30, 2026
Insider filing activity
RXRX insiders filed 11 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
RXRX news
- 1 Big Winner and 1 Loser From the Upcoming Anthropic IPOOct 31, 2026 · fool.com
- Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for InvestorsOct 30, 2026 · finance.yahoo.com
- Absci Sinks 8%, Schrödinger and Recursion Slide as AI Drug Discovery Stocks Give Back RallyOct 30, 2026 · tikr.com
- Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?Oct 29, 2026 · finance.yahoo.com
- Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings GrowthOct 29, 2026 · finance.yahoo.com
- Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 28, 2026 · finance.yahoo.com
- Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to ConsiderOct 26, 2026 · finance.yahoo.com
- Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3Oct 26, 2026 · finance.yahoo.com
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.